EUVIMEDEUVIMED entdecken
Crossref

Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors

Wenchao Wang iD, Dan Li, Jin Liu, Lei Li, Qi Zhang, Facai Zhang, Yang Liu, Yifan Zhang, Shuai Meng, Xuyang Shi, Hong Wang iD, Qingyong Li iD und 2 weitere

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19402-19420

DOI: 10.1021/acs.jmedchem.6c01714 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.07.2026. Verfasst von Wenchao Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, H…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Topoisomerase I Inhibitors, Urinary Bladder Neoplasms. Die Arbeit nennt 35 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Zhejiang Province, Zhejiang University of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer is a malignant tumor with a high incidence and mortality worldwide. Clinically, DNA-damaging agents such as cisplatin, irinotecan, and gemcitabine are commonly used, but their efficacy is often limited by acquired resistance. A key resistance mechanism involves the upregulation of PARP1 in response to drug-induced DNA single-strand breaks (SSBs), which diminishes the therapeutic effect. To overcome this obstacle, we designed and synthesized a series of united TOP1/PARP1 inhibitors that simultaneously induce SSBs via TOP1 inhibition and block their repair via PARP1 inhibition, converting repairable SSBs to lethal double-strand breaks (DSBs). Among these, compound D5 exhibited excellent dual-target inhibitory activity and effectively overcame cisplatin resistance, demonstrating potent antitumor efficacy in vitro and in vivo (TGI = 65.7%). Collectively, D5 represents a promising TOP1/PARP1 inhibitor for overcoming resistance to conventional DNA-damaging chemotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsTopoisomerase I InhibitorsUrinary Bladder NeoplasmsPoly (ADP-Ribose) Polymerase-1DNA Topoisomerases, Type IHumansAnimalsMiceStructure-Activity RelationshipDrug Resistance, NeoplasmCell Line, TumorDNA Repair

Substanzen

Antineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsTopoisomerase I InhibitorsPoly (ADP-Ribose) Polymerase-1DNA Topoisomerases, Type ITOP1 protein, humanPARP1 protein, human

Autor:innen und Institutionen

  • Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang310014, China.
  • College of Pharmaceutical Sciences, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang-Egypt Joint Laboratory on Intelligent Discovery of Marine Drugs, Zhejiang University of T…
  • Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang310014, China.

ORCID-Profile: Wenchao Wang, Hong Wang, Qingyong Li

Förderung

  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Zhejiang Province
  • Zhejiang University of Technology
  • National Key Research and Development Program of China
  • Zhejiang Key Laboratory of Green Manufacturing Technology for Chemical Drugs, Zhejiang University of Technology
  • Hangzhou Medical College
  • Zhejiang Provincial Government

Zitieren

APA

Wang, W., Li, D., Liu, J., Li, L., Zhang, Q., Zhang, F., Liu, Y., Zhang, Y., Meng, S., Shi, X., Wang, H., Li, Q., Zhang, D., & Mao, Z. (2026). Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of Medicinal Chemistry, 69(15), 19402-19420. https://doi.org/10.1021/acs.jmedchem.6c01714

Vancouver

Wang W, Li D, Liu J, Li L, Zhang Q, Zhang F, et al. Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of Medicinal Chemistry. 2026;69(15):19402-19420. doi:10.1021/acs.jmedchem.6c01714

BibTeX
@article{Wang2026,
  author = {Wang, Wenchao and Li, Dan and Liu, Jin and Li, Lei and Zhang, Qi and Zhang, Facai and Liu, Yang and Zhang, Yifan and Meng, Shuai and Shi, Xuyang and Wang, Hong and Li, Qingyong and Zhang, Dahong and Mao, Zujie},
  title = {Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {19402--19420},
  doi = {10.1021/acs.jmedchem.6c01714}
}
Kostenlos starten →